Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Alveolar antioxidant status in patients with acute respiratory distress syndrome

R. Schmidt, T. Luboeinski, P. Markart, C. Ruppert, C. Daum, F. Grimminger, W. Seeger, A. Günther
European Respiratory Journal 2004 24: 994-999; DOI: 10.1183/09031936.04.00120703
R. Schmidt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Luboeinski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Markart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Ruppert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Daum
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Grimminger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Seeger
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Günther
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

In the acutely inflamed lung, oxidant stress occurs within the alveolar compartment. Under these conditions, the regulation of low molecular weight antioxidants in the epithelial lining fluid is poorly understood. Therefore, antioxidant levels were measured in the bronchoalveolar lavage fluid (BALF) of patients with acute respiratory distress syndrome (ARDS; n=40) and in healthy volunteers (n=20).

Reduced glutathione (GSH), oxidised glutathione (GSSG; enzymatic assay), retinol (vitamin A), α-tocopherol (vitamin E), ascorbic acid (vitamin C), uric acid (all by HPLC), plasmalogens (1-alkenyl-2-acyl phospholipids), polyunsaturated fatty acids (PUFA; both by gas–liquid chromatography), and F2-isoprostanes (ELISA) were quantified. All values are expressed as concentrations in cell-depleted BALF.

GSSG (ARDS: 0.13±0.02 µM; control: 0.03±0.01 µM; mean±sem) and F2-isoprostanes (ARDS: 78±10 pM; control: 26±5 pM) were increased in ARDS, thus indicating oxidant stress. GSH levels in patients did not change significantly, whereas concentrations of vitamins A and C, vitamin E (ARDS: 77±15 nM; control: 26±3 nM) and uric acid (ARDS: 11.8±2.2 µM; control: 0.7±0.0 µM) were significantly elevated in ARDS. PUFA of total lipids, which may act as sacrificial antioxidants, increased by a factor of ∼3 in patients, but plasmalogens showed a significant decrease.

In conclusion, low molecular weight antioxidants are elevated in the alveolar compartment of patients with acute respiratory distress syndrome. Further research is warranted to elucidate the molecular mechanisms underlying this finding.

  • Acute lung injury
  • antioxidants
  • bronchoalveolar lavage
  • oxidative stress

This study was supported by the Deutsche Forschungsgemeinschaft (SCHM 1524/2-1), Bonn, Germany.

The alveolar compartment is permanently exposed to reactive oxygen (ROS) and nitrogen species (RNS) derived from inhaled air pollutants. The antioxidant defence system of the epithelial lining fluid consists of several low molecular weight compounds, such as reduced glutathione (GSH), ascorbic acid (vitamin C) and uric acid, lipophilic antioxidants, such as α-tocopherol (vitamin E), retinol (vitamin A) and plasmalogens (1-alkenyl-phospholipids), and antioxidant enzymes, with superoxide dismutases, catalase, and the glutathione peroxidases representing notable examples 1, 2. In the normal lung, complex and coordinated interactions of all antioxidant compounds provide protection of the distal lung structures from the damaging effects of oxidative attack.

Inflammation of the lung may result in activation of macrophages and neutrophils, and release of free radicals dueto respiratory burst. In addition, commonly used high inspiratory concentrations of oxygen may contribute to generation of free radicals 3. Accordingly, a large number of authors have provided evidence that oxidative-degradation products are elevated in acute respiratory distress syndrome (ARDS) patients, both in bronchoalveolar lavage fluid (BALF) and in exhaled breath condensate 4–6. This imbalance between newly generated oxidative compounds and the local antioxidative systems may well contribute to lung injury, resulting in increased capillary leakage 7, altered surfactant metabolism 2, 8, 9 and diminished surfactant function 10. This may further enhance alveolar oedema and collapse, frequently encountered in ARDS and acute lung injury (ALI).

Since ARDS/ALI are associated with elevated levels of reactive oxidants in BALF, and based on findings that blood antioxidant concentrations are reduced 11, it has long been hypothesised that alveolar antioxidants may be decreased inBALF of these patients 12. In view of the low molecular weight antioxidant compounds, data are conflicting and scarce. It has, for example, been suggested that GSH is reduced in BALF of ARDS patients 5, 13. Such analysis of single compounds may be complicated by the overall low levels of these substances in BALF, due to the 100–200-fold dilution of epithelial lining fluid (ELF) during the lavage procedure. Thus, highly sensitive and selective analytical procedures seem to represent a prerequisite for such analysis 1.

In light of these considerations, the present study was undertaken to carefully quantify single antioxidant compounds in BALF from 40 patients with ARDS. A total of 20 healthy volunteers served as controls. A significant increase was found for the majority of single antioxidant parameters investigated, with the exception of GSH and plasmalogens. It is concluded that increased oxidant burden in the distal lung regions of ARDS patients is followed or accompanied by an increase in antioxidant compounds.

Methods

Patient population

The study was conducted at the Dept of Internal Medicine, Justus-Liebig-University, Giessen, Germany, and included 40 patients fulfilling ARDS criteria, according to the definition of the American European Consensus Conference of ARDS 14. In detail, patients with ARDS had a history of acutely developing dyspnoea, arterial oxygen tension (Pa,O2)/inspiratory oxygen fraction (FI,O2) values of <200 mmHg (1 kPa=0.133 mmHg), pulmonary infiltrates, and pulmonary artery wedge pressures (PAWP) <18 mmHg or missing signs of left heart failure in echocardiography. Underlying reasons for thedevelopment of ARDS were pneumonia (n=31; primary ARDS), sepsis syndrome (n=8; secondary ARDS), and pancreatitis (n=1; secondary ARDS).

Exclusion criteria for all patients were PAWP >18 mmHg, lung contusion, pre-existing pulmonary diseases (fibrosis, chronic obstructive pulmonary disease), malignant underlying diseases, pregnancy and additional investigational drugs.

All patients received a standardised total parenteral nutrition regimen, including amino acids and trace elements (Aminomix 2®; Fresenius Kabi, Bad Homburg, Germany), lipids (Intralipid 20®; Baxter, Unterschleissheim, Germany), and a multivitamin preparation (Cernevit®-12; Baxter; 1vial·day−1). Cernevit-12 contains, among others, 10.2 mg α-tocopherol, 1.93 mg retinol palmitate and 125 mg ascorbic acid. All patients were mechanically ventilated, and fibreoptic bronchoscopy and bronchoalveolar lavage (BAL) were performed for diagnostic purposes directly after the onset of mechanical ventilation. A total of 20 healthy volunteers were lavaged in a similar manner. The protocol was approved by the local ethics committee of the Justus-Liebig-University. Each patient or their closest relatives provided informed consent. Demographic and basic clinical data are given in table 1⇓. The mean arterial oxygenation index (Pa,O2/FI,O2) was 143 mmHg in ARDS (all patients), 134 mmHg in patients with primary ARDS and 170 mmHg in patients with secondary ARDS. There was no significant difference in 28-day mortality between primary and secondary ARDS (table 1⇓). The recovery of the BALF was reduced by ∼20% in ARDS compared with healthy controls (table 1⇓).

View this table:
  • View inline
  • View popup
Table 1—

Demographic, clinical and routine laboratory data of the study population

Bronchoalveolar lavage

Flexible fibreoptic bronchoscopy was performed in all patients and controls by one physician in a standardised manner, as previously described 15. One segment of the lingula or the right middle lobe was lavaged with a total volume of 140 mL of sterile normal saline in seven equal aliquots. The recovered BALF was pooled, filtered through sterile gauze, and immediately centrifuged (300×g, 10 min, 4°C) to remove cells and membranous debris. Aliquots of BALF for antioxidant analysis were supplied with 0.01% butylated hydroxytoluene (BHT), frozen in liquid nitrogen and stored at −80°C. Staining and counting of the pelleted cells were performed according to routine standards. In keeping with the recommendations of the European Respiratory Society (ERS) Task Force 1, 16, 17, measurements of noncellular constituents were reported in concentrations per mL of recovered BALF.

Lipid and protein analysis

Lipids were extracted from BALF with chloroform/methanol, and phospholipid content was determined by spectrophotometric measurement, as previously described 15. Total proteins were analysed using a commercial assay (Bicinchoninic acid protein quantitation assay; Pierce, Bonn, Germany).

Antioxidant analysis

Reduced and oxidised glutathione

Total glutathione and oxidised glutathione (GSSG) were determined by enzymatic recycling assay originally described by Tietze 18, adapted for microtitre plates. GSSG was measured after masking of GSH with N-ethylmaleimide (NEM) and separation of GSH-NEM using solid-phase extraction.

Vitamin E and vitamin A

The hydrophobic vitamins α-tocopherol (vitamin E) and retinol (vitamin A) were simultaneously analysed by HPLC and diode array detection, according to the method of Catignani and Bieri 19. Retinol and α-tocopherol were simultaneously detected at 324 nm and 292 nm, respectively. Peak purity was checked using the corresponding ultraviolet spectra. Analytes were quantified by means of standard curves for each vitamin, after correction for internal standard (retinol acetate) variability.

Vitamin C and uric acid

Vitamin C (ascorbic acid (AA)) and uric acid (UA) were measured using HPLC, according to the method of Iriyama et al. 20. Detection was accomplished using a HP 1049A electrochemical detector (Agilent, Waldbronn, Germany), equipped with a Ag/AgCl working electrode and set at +800 mV.

Polyunsaturated fatty acids and plasmalogens

Total lipids were isolated as described previously, and fatty acids and plasmalogens were determined simultaneously using gas chromatography as previously described 21. The following fatty acids were used for calculation of polyunsaturated fatty acids (PUFA): 18:2, γ-18:3, 18:3, 20:2, 20:3(3), 20:3(6), 20:3(9), 20:4, 20:5, 22:3, 22:4, 22:5, and 22:6. The ratio ((weight of dimethylacetals (DMA)/weight of fatty acid methyl esters (FAME)) × 2) of the detected DMA to FAME indicated the relative amount of plasmalogens within the phospholipid fraction. Due to the lack of BHT-supplemented BALF material, plasmalogens and PUFA were only measured in 14 controls and 31 ARDS patients.

Analysis of F2-isoprostanes

F2-isoprostanes were quantified by means of an ELISA (Cayman Chemical, Ann Arbor, MI, USA). In brief, samples (500 µL BALF) were purified and concentrated by solid-phase extraction (3 mL Chromabond C18ec cartridges; Macherey Nagel, Düren, Germany), and F2-isoprostanes were eluted and subjected to ELISA, as detailed in the supplier's manual.

Statistical analysis

The results were expressed as mean±sem for each group. First, statistical analysis of differences between patients and controls and between patients with primary and secondary ARDS was performed by testing principle significance diversity (Kruskal-Wallis H-test), followed by comparison with a nonparametric test (Mann-Whitney U-Test). Values significantly different from control are indicated as p<0.05, p<0.01, and p<0.001.

Results

As anticipated, ARDS patients had markedly increased neutrophil and decreased macrophage counts in the BALF cell differential. Total BALF protein was highly elevated in ARDS, whilst total phospholipids did not differ significantly between patients and controls (table 1⇑).

In BALF from healthy controls, GSH was the most abundant antioxidant molecule (∼1.6 µM), followed by AA (∼0.5 µM) and UA (∼0.7 µM). The concentrations of the lipophilic antioxidants α-tocopherol (∼26 nM) and retinol (∼5 nM) were relatively low (table 2⇓).

View this table:
  • View inline
  • View popup
Table 2—

Absolute concentration of bronchoalveolar lavage fluid (BALF) oxidation markers and antioxidants

Patients with ARDS (0.13 µM; p<0.001) showed higher concentrations of GSSG compared with controls (0.03 µM; table 2⇑). Accordingly, F2-isoprostane levels, as markers for lipid peroxidation, were significantly elevated in ARDS, thus indicating oxidant stress (table 2⇑). The present authors were not able to detect considerable amounts of malondialdehyde both in controls and in patients with the currently used technique (HPLC with fluorescence detection), suggesting very low concentrations of this lipid degradation product in BALF.

The concentration of GSH was not different in ARDS as compared with controls (table 2⇑). The analysis of AA by HPLC revealed an approximately four-fold elevation in ARDS (2.4 µM; p<0.05; table 2⇑). Similarly, the concentration of UA was elevated in ARDS (11.8 µM; p<0.001) compared with controls (table 2⇑). The analysis of α-tocopherol (vitamin E) revealed a significant increase in ARDS (∼77 nM; table 2⇑). The concentrations of retinol (vitamin A) were approximately seven-fold elevated in ARDS (∼32 nM; p<0.001) compared with controls (table 2⇑).

In contrast to all other antioxidants investigated, plasmalogens were significantly decreased in ARDS, and this was true for both the absolute and relative (compared with total phospholipids) concentration (tables 2⇑ and 3⇓). The absolute and the relative content of PUFA, which may act as sacrificial agents under oxidant stress, were ∼2–3-fold elevated in ARDS compared with controls (tables 2⇑ and 3⇓).

View this table:
  • View inline
  • View popup
Table 3—

Relative concentration of bronchoalveolar lavage fluid (BALF) oxidation markers and antioxidants

In an attempt to compensate for the dilution variability during BAL procedure, phospholipid coefficients were calculated for all measured parameters (table 3⇑). When using the phospholipid concentration as a denominator, nearly the same results as described previously were obtained. In contrast, when performing urea correction (urea concentration in blood/urea concentration in BALF), no significant difference in GSSG and F2-isoprostane levels were observed (data not given in detail). Urea-corrected GSH was significantly decreased in ARDS (71.0 µM versus 216.5 µM in controls; p<0.001), UA concentrations were still significantly elevated (ARDS: 342 µM versus 100 µM in controls; p<0.001), retinol values were approximately threefold elevated in ARDS, whilst all other antioxidant compounds showed only minor differences compared with controls (data not given in detail).

Patients with ARDS were further divided into primary ARDS (n=31) and secondary ARDS (n=9). Only minor differences were observed in GSH levels in primary ARDS (1.5±0.4 µM) and in secondary ARDS (1.4±0.3 µM). In contrast, the absolute concentrations of AA and UA were lower in primary ARDS compared with secondary ARDS (table 2⇑), but these differences were not significant. Additionally, when using the total phospholipid concentration as a denominator, only minor differences between primary and secondary ARDS could be detected (table 3⇑). The concentrations of plasmalogens and PUFA did not change between primary and secondary ARDS.

The results of correlational analysis with the data presented here and markers for severity of the disease (Pa,O2/FI,O2) and clinical outcome (28-day mortality) revealed that no significant correlation could be detected when comparing antioxidant and oxidative degradation product levels with Pa,O2/FI,O2 values. Furthermore, no significant difference could be observed between 28-day survivors and nonsurvivors, in view of the addressed markers.

Discussion

The present study sought to investigate the regulation of low molecular weight antioxidant molecules in ARDS. In contrast to other diseases with underlying inflammatory events, such as asthma 22 and bronchiolitis obliterans syndrome in lung transplantation 23, less is known about the regulation and distribution of alveolar low molecular weight antioxidants in these entities. Recent investigations in ARDS mainly focused on glutathione levels and BALF concentrations of some antioxidant enzymes and proteins. In the present study, GSH, the hydrophilic antioxidants AA and UA, and the membrane-associated antioxidants plasmalogens, vitamins E and A were identified as the predominant low molecular weight antioxidants in BALF of healthy individuals. Only very small amounts of oxidation products, such as GSSG and F2-isoprostanes, were detected.

Under conditions of ARDS, markers of oxidant stress (GSSG and F2-isoprostanes) were several-fold elevated, consistent with previous investigations 5, 6. The relatively low concentration of F2-isoprostanes in BALF suggests that generation of these oxidised lipids is limited under these conditions or that they are rapidly cleared from alveolar space, either by metabolic pathways or by transfer into the blood compartment.

Upregulation of the majority of the investigated antioxidant compounds was consistently observed. The most abundant alveolar antioxidant GSH, however, showed no significant change compared with controls. This is in contrast to previous reports, in which significant reductions in GSH levels were found in ARDS 5, 13. The main reason for this discrepancy may be related to the use of a urea coefficient for correction of BAL variability in these studies. As has been repeatedly discussed, BAL/blood urea quotient-based correction of the concentration of BALF compounds is prone to pitfalls, which may arise from the rapid diffusion of urea, especially through the leaky barrier in inflammatory lung diseases. Also, the existing oedema fluid, enriched with urea, may lead to falsely too low values and to large interpatient variation 24. In line with such reasoning, similar changes in the concentration of GSH were observed, as compared with the previous studies, when applying the urea-based correction method. In the current study, the guidelines of the ERS Task Force Report were followed 1, 16, 17, and all values were reported as concentrations per mL of BALF. Additionally, as suggested by the ERS Task Force, the recovery of instilled lavage fluid was reported, and the BALF phospholipid concentration was used as a denominator.

The hydrophilic antioxidants (AA and UA) appeared to be more upregulated compared with the lipophilic antioxidants (vitamins A and E). PUFA, which may act as sacrificial antioxidants, were also markedly elevated in the current patient groups.

In contrast to all other antioxidants assessed here, plasmalogens, which are believed to represent integral components of pulmonary surfactant 25 and powerful antioxidants 26, were decreased in both patient groups, inview of their absolute as well as their relative content (compared with total phospholipids). On the one hand, this may suggest increased degradation and/or impaired synthesis/secretion on the other hand. Interestingly, this clearly differs from vitamins A and E, which were found here to be clearly upregulated and are also actively secreted with pulmonary surfactant by type II cells 25.

In the current investigation, a persistent oxidative stress was observed in distal lung structures in ARDS patients. Despite the fact that alveolar antioxidants are increased, an excess of oxidative forces persists, ultimately leading to oxidant/antioxidant imbalance. As a result, various forms of molecular damage occur in response to the formation of ROS and RNS, among these are lipid peroxidation, DNA and protein damage. This may have several consequences, as follows: 1) parenchymal and endothelial cells are damaged by ROS 27, which may lead to increased vascular permeability 28, 29; 2) damage of surfactant-specific proteins and chemical modification by reactive radicals may markedly contribute to impaired surface activity and have indeed been observed in several studies 4; and 3) probably even more important than direct surfactant damage, oxidant-induced disturbances in alveolar type II cell surfactant synthesis and metabolism may account for the pronounced impairment of surfactant function encountered in ARDS 8, 9, 30.

Despite a wealth of investigations, the precise modes of action of low molecular weight antioxidants in biological fluids and tissues, the relative importance of individual antioxidants, and their individual impact on total antioxidant capacity in the alveolar compartment remain poorly understood. Furthermore, the sources of antioxidants and their metabolism in the ELF are still unclear 1.

The most prominent finding of the current study, the increase in antioxidants in the alveolar compartment, may provoke the speculation that antioxidant metabolism in alveolar epithelial cells is accelerated under oxidative stress during ALI. However, it should be kept in mind that the currently used study design cannot further strengthen such a hypothesis, mainly because total BALF antioxidant levels only reflect net effects of different processes. Further research is necessary to investigate antioxidant metabolism in lung epithelial cells under the conditions of oxidative stress. Recent work has focused mainly on the regulation of glutathione. For example, Rahman et al. 31 found that both glutathione and γ-glutamylcysteine synthetase levels increase in alveolar type II cells after oxidant treatment. This may be induced by activation of redox-sensitive transcription factors, such as nuclear factor-κB and activator protein-1, which are involved in regulation of antioxidant genes. A recent study by Blomberg et al. 32 showed that single alveolar antioxidant levels are rapidly restored after depletion by diesel exhaust, indicating that there are fast metabolic pathways in the lung. During tobacco-smoke exposure 33 and in patients with asthma 34, GSH was found to be increased in BALF. Furthermore, pre-exposure of animals to sublethal oxidant stress, including ozone, hypoxia and hyperoxia, resulted in increased antioxidant levels 35, 36 and enhanced tolerance to subsequent hyperoxic challenge 36. Taken together, these findings may indicate the adaptive capability of the lung in the course of oxidant-induced lung injury. Another aspect that should be considered is that the mode of ventilation during ARDS may also alter antioxidant gene expression and antioxidant release. Copland et al. 37 convincingly demonstrated that the mode of ventilation has a profound impact on gene expression in the lung. As compared to a nonventilated lung, they found increased levels of proinflammatory genes (e.g. interleukin-1β) in bronchiolar epithelium cells by using cell picking, in situ hybridisation and macroarray techniques after high-frequency ventilation. Significant up- and downregulation of several genes were observed already after 30 min of high-frequency ventilation. The authors hypothesise that mechanical stretch during high-frequency ventilation alters the lung gene profile significantly, and that these gene alterations precede the lung injury. Although these authors did not present data on antioxidant genes, these results evidently demonstrate the readiness of the lung to respond to mechanical ventilation with a profound change in the gene expression pattern that may, of course, also include antioxidant genes.

Taken together, in acute respiratory distress syndrome, the current results suggest that the alveolar oxidative challenge is associated with a net increase of low molecular weight antioxidants. Future studies will have to elucidate whether this local increase in low molecular weight antioxidants is due to local production or spillover from the blood compartment. Nevertheless, the global antioxidant capacity of the epithelial lining fluid, despite the increase in single antioxidant compounds, seems unable to fully counterbalance the increased oxidative burden. Future studies may help to clarify the relative importance of single antioxidants in protecting the lung from oxidative attack.

Acknowledgments

Portions of this report have been undertaken by T. Luboeinski in partial requirement for his medical thesis.

  • Received October 28, 2003.
  • Accepted August 16, 2004.
  • © ERS Journals Ltd

References

  1. ↵
    Kelly JF, Buhl R, Sandström T. Measurement of antioxidants, oxidants and oxidation products in bronchoalveolar lavage fluid. Eur Respir Rev 1999;9:93–98.
  2. ↵
    Putman E, van Golde LM, Haagsman HP. Toxic oxidant species and their impact on the pulmonary surfactant system. Lung 1997;175:75–103.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Lang JD, McArdle PJ, O'Reilly PJ, Matalon S. Oxidant-antioxidant balance in acute lung injury. Chest 2002;122:Suppl. 6, 314S–320S.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Lamb NJ, Gutteridge JM, Baker C, Evans TW, Quinlan GJ. Oxidative damage to proteins of bronchoalveolar lavage fluid in patients with acute respiratory distress syndrome: evidence for neutrophil-mediated hydroxylation, nitration, and chlorination. Crit Care Med 1999;27:2028–2030.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Bunnell E, Pacht ER. Oxidized glutathione is increased in the alveolar fluid of patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1993;148:1174–1178.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Carpenter CT, Price PV, Christman BW. Exhaled breath condensate isoprostanes are elevated in patients with acute lung injury or ARDS. Chest 1998;114:1653–1659.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Messent M, Sinclair DG, Quinlan GJ, Mumby SE, Gutteridge JM, Evans TW. Pulmonary vascular permeability after cardiopulmonary bypass and its relationship to oxidative stress. Crit Care Med 1997;25:425–429.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Holm BA, Matalon S, Finkelstein JN, Notter RH. Type II pneumocyte changes during hyperoxic lung injury and recovery. J Appl Physiol 1988;65:2672–2678.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Crim C, Longmore WJ. Sublethal hydrogen peroxide inhibits alveolar type II cell surfactant phospholipid biosynthetic enzymes. Am J Physiol 1995;268:L129–L135.
  10. ↵
    Gilliard N, Heldt GP, Loredo J, Redl H, Merritt TA, Spragg RG. Exposure of the hydrophobic components of porcine lung surfactant to oxidant stress alters surface tension properties. J Clin Invest 1994;93:2608–2615.
  11. ↵
    Leff J, Parsons PE, Day CE, et al. Serum antioxidants as predictors of adult respiratory distress syndrome in patients with sepsis. Lancet 1993;341:777–780.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    Comhair SA, Erzurum SC. Antioxidant responses to oxidant-mediated lung diseases. Am J Physiol 2002;283:L246–L255.
    OpenUrl
  13. ↵
    Pacht ER, Timerman AP, Lykens MG, Merola AJ. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest 1991;100:1397–1403.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Bernard GR, Artigas A, Brigham KL, et al. The American-European consensus conference on ARDS. Am J Respir Crit Care Med 1994;149:818–824.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    Günther A, Siebert C, Schmidt R, et al. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996;153:176–184.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Baughman RP, Rennard SI. Bronchoalveolar lavage: general approaches to correct for variability of dilution and lung permeability. Eur Respir Rev 1999;9:28–31.
  17. ↵
    Ward C, Effros RM, Walters EH. Assessment of epithelial lining fluid dilution during bronchoalveolar lavage. Eur Respir Rev 1999;9:32–37.
  18. ↵
    Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 1969;27:502–522.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    Catignani GL, Bieri JG. Simultaneous determination of retinol and α-tocopherol in serum or plasma by liquid chromatography. Clin Chem 1983;29:708–712.
    OpenUrlFREE Full Text
  20. ↵
    Iriyama K, Yoshiura M, Iwamoto T, Ozaki Y. Simultaneous determination of uric and ascorbic acid in human serum by reversed-phase high-performance liquid chromatography with electrochemical detection. Anal Biochem 1984;141:238–243.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    Eder K. Gas chromatographic analysis of fatty acid methyl esters. J Chromatogr B Biomed Appl 1995;671:113–131.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Kelly JF, Mudway I, Blomberg A, Frew A, Sandström T. Altered lung antioxidant status in patients with mild asthma. Lancet 1999;354:482–483.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Riise GC, Williams A, Kjellstrom C, Schersten H, Andersson BA, Kelly FJ. Bronchiolitis obliterans syndrome in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in the lung. Eur Respir J 1998;12:82–88.
    OpenUrlAbstract
  24. ↵
    von Wichert P, Joseph K, Müller B, Franck WM. Bronchoalveolar lavage. Quantification of intraalveolar fluid. Am Rev Respir Dis 1993;147:148–152.
    OpenUrlPubMedWeb of Science
  25. ↵
    Tölle A, Kolleck I, Schlame M, Wauer R, Stevens AP, Rüstow B. Effect of hyperoxia on the composition of the alveolar surfactant and the turnover of surfactant phospholipids, cholesterol, plasmalogens and vitamin E. Biochim Biophys Acta 1997;1346:198–204.
    OpenUrlPubMed
  26. ↵
    Sindelar PJ, Guan Z, Dallner G, Ernster L. The protective role of plasmalogens in iron-induced lipid peroxidation. Free Radic Biol Med 1999;26:318–324.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    Martin WJ, Gadek JE, Hunninghake GW, Crystal RG. Oxidant injury of lung parenchymal cells. J Clin Invest 1981;68:1277–1288.
  28. ↵
    Harlan JM, Killen PD, Harker LA, Striker GE, Wright DG. Neutrophil-mediated endothelial injury in vitro mechanisms of cell detachment. J Clin Invest 1981;68:1394–1403.
  29. ↵
    Tate RM, Vanbenthuysen KM, Shasby DM, McMurtry IF, Repine JE. Oxygen-radical-mediated permeability edema and vasoconstriction in isolated perfused rabbit lungs. Am Rev Respir Dis 1982;126:802–806.
    OpenUrlPubMedWeb of Science
  30. ↵
    Guthmann F, Kolleck I, Schachtrup C, Schlame M, Spener F, Rüstow B. Vitamin E deficiency reduces surfactant lipid biosynthesis in alveolar type II cells. Free Radic Biol Med 2003;34:663–673.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    Rahman I, Bel A, Mulier B, Donaldson K, MacNee W. Differential regulation of glutathione by oxidants and dexamethasone in alveolar epithelial cells. Am J Physiol 1998;275:L80–L86.
  32. ↵
    Blomberg A, Sainsbury C, Rudell B, et al. Nasal cavity lining fluid ascorbic acid concentration increases in healthy human volunteers following short term exposure to diesel exhaust. Free Radic Res 1998;28:59–67.
    OpenUrlPubMedWeb of Science
  33. ↵
    Cantin AM, North SL, Hubbard RC, Crystal RG. Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol 1987;63:152–157.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Smith LJ, Houston M, Anderson J. Increased levels of glutathione in bronchoalveolar lavage fluid from patients with asthma. Am Rev Respir Dis 1993;147:1461–1464.
    OpenUrlPubMedWeb of Science
  35. ↵
    Kodavanti UP, Costa DL, Dreher KL, Crissman K, Hatch GE. Ozone-induced tissue injury and changes in antioxidant homeostasis in normal and ascorbate-deficient guinea pigs. Biochem Pharmacol 1995;17:243–251.
    OpenUrl
  36. ↵
    Jackson RM, Frank L. Ozone-induced tolerance to hyperoxia in rats. Am Rev Respir Dis 1984;129:425–429.
    OpenUrlPubMedWeb of Science
  37. ↵
    Copland IB, Kavanagh BP, Engelberts D, McKerlie C, Belik J, Post M. Early changes in lung gene expression due to high tidal volume. Am J Respir Crit Care Med 2003;168:1051–1059.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
View this article with LENS
Vol 24 Issue 6 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Alveolar antioxidant status in patients with acute respiratory distress syndrome
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Alveolar antioxidant status in patients with acute respiratory distress syndrome
R. Schmidt, T. Luboeinski, P. Markart, C. Ruppert, C. Daum, F. Grimminger, W. Seeger, A. Günther
European Respiratory Journal Dec 2004, 24 (6) 994-999; DOI: 10.1183/09031936.04.00120703

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Alveolar antioxidant status in patients with acute respiratory distress syndrome
R. Schmidt, T. Luboeinski, P. Markart, C. Ruppert, C. Daum, F. Grimminger, W. Seeger, A. Günther
European Respiratory Journal Dec 2004, 24 (6) 994-999; DOI: 10.1183/09031936.04.00120703
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS
  • Effect of prior statin therapy on capillary permeability in the lungs after cardiac or vascular surgery
  • VEGF levels in the alveolar compartment do not distinguish between ARDS and hydrostatic pulmonary oedema
Show more Original Articles: ARDS

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society